After informed consent is obtained, subjects will enter into a Screening period, which will last up to 28 days. Once all eligibility criteria are confirmed and the subject is randomized, subjects will receive the IP or placebo as a 2-week supply of capsules. All randomized subjects will receive the IP or matching placebo for a total of 12 weeks. No more than 2 HBeAg positive subjects can receive placebo per the randomization scheme.